MOUNTAIN VIEW, Calif., Dec. 20, 2017 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management automation, analytics software, and medication adherence solutions for healthcare organizations, today announced that UPMC has chosen to enhance control, efficiency and safety for medication management with Omnicell's newest pharmacy automation and IV compounding solutions.
UPMC is adding the Omnicell® XR2 Automated Central Pharmacy System, IVX Workflow sterile compounding workflow technology, and i.v.STATIONTM for non-hazardous robotic compounding to pharmacy operations at its flagship hospitals, UPMC Presbyterian and UPMC Shadyside. UPMC will build on an existing investment in automation hardware and workflow software solutions to support a better patient medication experience.
"At Omnicell, we're continuously delivering new innovation to help health care partners like UPMC attain the vision of the automated pharmacy of the future," said Randall Lipps, chairman, CEO, president and founder of Omnicell. "Together we're revolutionizing medication management and transforming pharmacy's role in health care."
XR2 is an automated system, designed to meet the unique and evolving needs of pharmacy operations, through scalable technology that automates and streamlines critical workflows for the storing, managing and dispensing of patient medications. The system utilizes robotic technology to eliminate numerous manual tasks, freeing up time for more value-added work.
IVX Workflow offers an innovative approach to sterile compounding workflow, through a compact all-in-one package that uses integrated barcode scanning, gravimetric or volumetric verification, advanced image recognition, photo documentation and label printing to support safe, accurate, and streamlined IV sterile compounding. IVX Workflow is powered by Omnicell IVX Cloud, a fully web-based software suite designed to manage all aspects of IV workflow operation across a hospital or health system.
Once implemented in conjunction with i.v.STATION, a fully automated IV compounding solution for preparing non-hazardous, ready-to-administer doses, UPMC expects to reduce pharmacy outsourcing costs for sterile compounding, while enhancing patient safety and reduce pharmacy outsourcing costs for sterile compounding.
Omnicell's broad portfolio of solutions for medication management from hospital to home supports an autonomous approach, leveraging hardware and workflow solutions, real-time predictive intelligence, and performance-driven partnerships to drive ongoing satisfaction and transform patient-centered care.
Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on improving care across the entire healthcare continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient's home.
Over 4,000 customers worldwide use Omnicell® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety.
The Omnicell SureMed® solution provides innovative medication adherence packaging to help reduce costly hospital readmissions. These medication adherence solutions are used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom. These pharmacies are served via Omnicell's sales channels and our solutions enable them to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.
Recent acquisitions, including Ateb, have added distinct capabilities, particularly in central pharmacy, IV robotics and pharmacy software, creating the broadest medication management product portfolio in the industry.
For more information about Omnicell, Inc. please visit www.omnicell.com.
- All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company's external website, omnicell.com.
- Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
- All other brand or product names may be trademarks or registered trademarks of their respective companies.
SOURCE Omnicell, Inc.